Sodium-Glucose Cotransporter 2 Inhibition in Type 2 Diabetes Management
Summary
Sodium-glucose cotransporter 2 inhibitors have emerged as a transformative class of oral antidiabetic agents targeting renal glucose reabsorption. By blocking SGLT2 in the proximal tubule, these molecules promote urinary glucose excretion, lowering plasma glucose independently of insulin action. Beyond glycaemic control, SGLT2 inhibition improves weight management, reduces blood pressure and exerts cardioprotective and renoprotective effects through metabolic shifts towards increased ketone utilisation and modulation of inflammatory pathways. Large outcome trials have demonstrated reductions in cardiovascular events and slowing of diabetic kidney disease progression, establishing this class as a cornerstone in type 2 diabetes management. Integration of these agents into treatment algorithms emphasises their global impact and versatility in diverse patient populations, while ongoing research explores mechanistic underpinnings and potential novel indications.
Research from Nature Portfolio
Recent studies have elucidated the immunometabolic mechanisms underlying the cardiovascular benefits of SGLT2 inhibitors. One investigation demonstrated that SGLT2 inhibition attenuates activation of the NLRP3 inflammasome in macrophages, reducing interleukin-1β secretion. This effect was linked to elevated circulating β-hydroxybutyrate and lowered insulin levels, suggesting an anti-inflammatory cascade that complements direct glucose-lowering actions and may account for observed reductions in major adverse cardiac events.
Sodium-Glucose Cotransporter 2 Inhibition in Type 2 Diabetes Management publication trend
The graph below shows the total number of articles in sodium-glucose cotransporter 2 inhibition in type 2 diabetes management across all publications each year (not limited to Nature Index journals).
Technical terms
Sodium-glucose cotransporter 2 (SGLT2): A renal transporter in proximal tubular cells responsible for reclaiming the majority of filtered glucose.
NLRP3 inflammasome: A multiprotein complex in immune cells that, when activated, promotes maturation and release of pro-inflammatory cytokines such as interleukin-1β.
Urinary glucose excretion (UGE): Elimination of glucose in the urine, increased by SGLT2 inhibition, contributing to reduced plasma glucose.
β-Hydroxybutyrate (BHB): A ketone body whose levels rise during enhanced fat oxidation and have been implicated in signalling pathways that suppress inflammation.
References
- Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia (2019).
- SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nature Communications (2020).
- The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes. Journal of Clinical Medicine (2019).
About these summaries
This Nature Research Intelligence Topic summary is created with the cited references and a large language model. We take care to ground generated text with facts, and have systems in place to gain human feedback on the overall quality of the process in line with our AI principles. We strive to create accurate and useful summaries for people unfamiliar with the research topic and that supports this goal. These pages are a beta release and will be updated as we learn how best to help people gain value from a research topic summary.
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.